Journal article
Heterologous prime-boost vaccine using antigen-loaded microparticles and adenovirus (encoding antigen) enhances cellular immune responses and antitumor activity
International journal of pharmaceutics, Vol.638, 122932
04/07/2023
DOI: 10.1016/j.ijpharm.2023.122932
PMID: 37031810
Abstract
Heterologous prime-boost vaccines have the potential to promote higher immune responses than homologous prime-boost vaccines and were used in this murine study to investigate the effect on the magnitude of the cellular (and humoral) antigen-specific immune responses and antitumor efficacy when a microparticle formulation (prime) is combined with an adenoviral vaccine (boost). Specifically, the prime comprised chick egg ovalbumin (OVA; 25 µg/dose), used here as a model tumor antigen (TA), encapsulated in microparticles (∼700 nm diameter) made from the biodegradable polymer, 50:50 poly(lactic-co-glycolic acid) (PLGA); while attenuated adenovirus (type 5) encoding OVA (Ad5OVA; 10
PFU/dose) was employed as the boost. The ability of OVA-loaded microparticles to enhance OVA-specific antibody responses, OVA-specific CD3+CD8+ T cell responses and antitumor activity (i.e., protecting against OVA-expressing tumor-challenge) to the heterologous prime-boost vaccine was investigated; and it was found that this prime-boost combination could significantly enhance OVA-specific cellular responses compared to all other vaccination groups and was the only group to confer a significant survival advantage over the unvaccinated group (naïve) in a prophylactic animal tumor model. This finding illustrates the potential for combining TA-loaded PLGA-based microparticles with other vaccine formats to improve tumor-specific cellular immune responses.
Details
- Title: Subtitle
- Heterologous prime-boost vaccine using antigen-loaded microparticles and adenovirus (encoding antigen) enhances cellular immune responses and antitumor activity
- Creators
- Alexis A Ellis - University of IowaSean M Geary - University of IowaAliasger K Salem - University of Iowa
- Resource Type
- Journal article
- Publication Details
- International journal of pharmaceutics, Vol.638, 122932
- DOI
- 10.1016/j.ijpharm.2023.122932
- PMID
- 37031810
- NLM abbreviation
- Int J Pharm
- ISSN
- 0378-5173
- eISSN
- 1873-3476
- Language
- English
- Date published
- 04/07/2023
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Dental Research; Chemical and Biochemical Engineering
- Record Identifier
- 9984388755002771
Metrics
9 Record Views